QIAGEN $8.7B Strategic Review: Jonathan Pratt Takes Over
QIAGEN’s data room is reportedly open. Jonathan Pratt is not inheriting a normal CEO job — he is walking into an $8.7 billion private-equity audition.
QIAGEN has hired Jonathan Pratt while its data room is reportedly open and it weighs strategic options worth roughly $8.7 billion. He is not inheriting a normal CEO job; he is walking into a private-equity audition.
That is not a normal CEO job. It is a board saying, politely, that the business may be for sale.
And good on them for not pretending otherwise.
Too many boards run CEO searches as theatre: smiling photos, vague language about “the next chapter,” a bloke with a nice résumé, and zero acknowledgement that the real work is happening behind closed doors. QIAGEN has at least put the pieces on the table. Thierry Bernard steps down as CEO on September 1, stays through year-end to hand over the keys, and Jonathan Pratt arrives as the supervisory board continues its strategic review.
That combination matters more than the press release language. A company does not appoint an external CEO with more than 25 years across life sciences and laboratory technology, then keep a strategic review ticking along, unless the board wants maximum optionality.
Jonathan Pratt is a signal, not merely a successor
Pratt most recently ran Filtration Group through its sale to Parker-Hannifin, which closed in August for $9.25 billion. Parker expects the acquisition to add about $1.8 billion to its fiscal 2027 sales in the first 10.5 months of ownership and says it is targeting roughly $220 million in pre-tax cost synergies by the end of year three.
That is a proper operating transaction, not a vanity acquisition.
Before Filtration Group, Pratt held senior roles at Waters, Beckman Coulter Life Sciences and Pall. In other words, he has spent his career in exactly the sort of unsexy-but-critical businesses that make modern science work: instruments, consumables, workflows, lab infrastructure and the service machinery around them.
That experience is useful whether QIAGEN remains independent or changes hands. But it is especially useful in a sale process because buyers do not pay top dollar for PowerPoint ambition. They pay for a management team that can explain where growth comes from, which costs can come out, how sticky customers are, what the product roadmap requires, and which ugly operational surprises are hiding in the cupboard.
Pratt has just helped take a business through a $9.25 billion transaction. The board has not hired him because he can give a good town-hall speech. They have hired someone who understands what institutional buyers interrogate when the spreadsheet gets serious.
QIAGEN is not broken — which is why the board has choices
This is the overlooked part. QIAGEN is not bringing in a firefighter.
Its second-quarter 2026 net sales were $535 million, flat year on year but ahead of the company’s own outlook for an approximately 2% constant-exchange-rate decline. Adjusted diluted earnings per share came in at $0.62, above guidance of at least $0.60. Adjusted operating margin was 29.4%. First-half operating cash flow was $301 million.
Those are not disaster numbers. They are the numbers of a decent business dealing with a patchy market.
QIAGEN also reaffirmed full-year guidance for net-sales growth of about 1% to 2% at constant exchange rates and adjusted diluted EPS of at least $2.43. Its growth pillars — including sample technologies, QIAcuity and QIAGEN Digital Insights — grew about 5% in the second quarter on that basis.
The soft spots were real. U.S. immigration-testing demand hit QuantiFERON, and QIAstat-Dx faced a tough comparison against a stronger respiratory-testing period a year earlier. But that is a long way from saying the business has run out of road.
This distinction matters. A weak company sells because it has run out of options. A profitable, cash-generative company can run a review because it has options. The board can sell. It can remain independent. It can use buyer interest to sharpen its capital allocation and operating plan. It can negotiate from a position of relative strength.
That is the upside. The risk is that a board becomes so enchanted by the possibility of a premium bid that it stops properly running the company it already owns.
The strategic review changes the CEO’s real scorecard
Reportedly, QIAGEN has opened a data room and talks with potential buyers including EQT and KKR are continuing. Treat that as a live possibility, not a concluded deal. A data room is not a signed cheque. Plenty of deals die when buyers get into the detail, financing costs shift, regulators get interested, or the price simply stops making sense.
Still, it means Pratt has a weird first assignment.
Most incoming CEOs get 100 days to listen, learn the people, diagnose the commercial engine and decide what to change. Pratt may have to do all of that while keeping customers calm, staff focused, forecasts intact, and potential acquirers convinced they are looking at a business with momentum rather than a company waiting around to be bought.
That is harder than it sounds.
The board has given itself a sensible transition structure: Bernard remains until the end of 2026. On paper, that is continuity. In practice, it works only if the lines are brutally clear. One CEO cannot be talking to customers about the future while another is quietly making the actual calls. One leadership team cannot run two strategies: “build for the next decade” and “polish for a buyer.”
Pick the operating plan that creates the most value as a standalone business. Then let buyers pay for that plan if they want it.
Anything else is how companies start underinvesting in product, delaying difficult hires and dressing up short-term margin as strategy. It looks neat in a deal book. It usually leaves a mess afterwards.
Here is the contrarian view: a sale may not be the best outcome
Everyone loves the drama of a private-equity bid because it creates a clean headline and a number people can argue about over lunch. But shareholders should not automatically assume a sale is the winning move.
QIAGEN sits in a category where customer trust, recurring consumables, installed instruments, regulatory know-how and scientific credibility compound over years. Those are attractive traits for private equity, obviously. They are also exactly the traits that can make a well-run public company valuable over a long period.
The best outcome is not “sell.” The best outcome is: make a buyer pay more than the value of QIAGEN becoming a sharper, better allocated independent business under Pratt.
If the board cannot get that price, it should walk.
That takes backbone because markets often reward a deal announcement more quickly than they reward three years of dull operational discipline. But boards are not paid to provide excitement. They are paid to make the correct long-term capital-allocation decision.
Pratt’s Filtration Group experience gives him credibility with financial buyers. More importantly, it should give him confidence not to bend the knee to one. He has seen what a serious buyer values. That should help QIAGEN run itself in a way that is valuable whether a deal happens or not.
What this means for you
If you run a business, do not wait for a sale process to discover whether your company is understandable.
Start tomorrow with four questions:
1. Can your leadership team explain growth in numbers, not adjectives? QIAGEN can point to $535 million in quarterly sales, a 29.4% adjusted operating margin, $301 million in first-half operating cash flow, and specific growth pillars. You need that same clarity — even if your numbers are much smaller.
2. Would a buyer find your mess in an afternoon? Your contracts, customer concentration, key-person risk, product economics, churn, staff incentives and reporting discipline should be deal-ready before anyone asks. Not because you must sell, but because clean businesses make better decisions.
3. Do you have a succession plan that creates options? Bernard staying through December is useful only if Pratt has authority from day one. Build successors before you need them. A rushed handover is expensive, distracting and usually obvious to everyone outside the building.
4. Are you optimising for a transaction or for a great business? The answer should be the latter. A great standalone business attracts buyers. A business cosmetically prepared for sale often attracts discount hunters.
That is the actual lesson in QIAGEN’s CEO change. The board has brought in a man who knows how a serious industrial-science business is bought and sold. Now it needs to ensure he has the freedom to build one worth keeping.
That is how you retain leverage. In a boardroom, in a negotiation, and in business generally: make sure you are valuable enough to walk away.